|Vol.1 Issue 8||gman.myeloma.org||December 2015|
Four Treatments Approved in the US This Year
This year, the US Food and Drug Administration (FDA) approved four new myeloma drugs, three of which were approved just last month. Most recently approved was Empliciti (elotuzumab), a monoclonal antibody developed by Bristol-Myers Squibb and AbbVie, for use in combination with lenalidomide and dexamethasone to treat patients who have received at least one prior therapy. Ninlaro (Ixazomib) from Takeda Oncology, an oral, once-weekly proteasome inhibitor, was approved for use in combination with lenalidomide and dexamethasone to treat patients who have received at least one prior therapy. Just a few days prior to the approval of Ninlaro, the FDA approved Darzalex (daratumumab) from Janssen, which is the first monoclonal antibody approved for treating myeloma. It is given by infusion and works by helping the immune system attack cancer cells. It will be used to treat patients who have received at least three prior therapies. And finally, early in the year, Farydak (panobinostat) from Novartis became the first histone deacetylase (HDAC) inhibitor approved to treat myeloma.. It is intended for patients who have received at least two prior standard therapies and is to be used in combination with bortezomib and dexamethasone. Farydak was also approved for use in the EU this past September. What a great year for patients in the US. We hope to see these drugs approved for use in other global markets moving forward.
Join Us Virtually at ASH
On December 4th at 0700 Eastern Standard Time, 1200 UTC, GMAN will host a short meeting during the American Society of Hematology annual event in Orlando, Florida, USA. The meeting will run for two hours and focus on upcoming events and issues for GMAN in 2016. For those that would like to attend, but are unable to travel, please join the meeting here at 0700 Eastern Standard Time. Video and audio will be enabled for online participants to participate via their computer. If you plan to attend online, please test your system prior to joining the meeting. If you would like a copy of the agenda, email Ray Wezik at email@example.com.
GMAN on Social Media
If you would like to share news about GMAN with your organization’s followers, consider following GMAN on Twitter or Facebook. A link to our monthly newsletter is placed on these social media sites each month, as well as other news, such as this article on GMAN’s latest meeting in Rome. If you are not yet a part of these social media sites, join now! It is free and a fantastic way to connect with GMAN members or your patient groups wherever you are.
For 21 years Candy Heberlein and the Foundation for the Advancement of Bone Marrow Transplantation Switzerland have held a fairy tale theatre for children with cancer as well as the children of cancer patients. With over 500 guests each year, the event is quite popular and is done free of charge for the kids. Following the play, the children are treated to drinks, cakes and other treats. It is a wonderful holiday event that allows the myeloma community a chance to give back to the youngest affected by cancer and make Christmas time special for everyone.
On November 23rd, AMEN in Israel started a new public awareness campaign focusing on the need for more combination therapies in the country. As part of the awareness campaign a film was created that illustrates the passage of time throughout life and the desire of myeloma patients to experience their lives to the fullest. While the video is in Hebrew, it ends with the message, “multiple myeloma patients asking for more time.” AMEN hopes that through public support, approvals for more treatment options will occur that can allow myeloma patients to live longer, healthier lives. Click here to view the campaign. The Google Chrome web browser offers a native translation tool to see the campaign website in your language.
To submit a news story for publication, please contact
Raymond Wezik, Global Advocacy Executive, International Myeloma Foundation at firstname.lastname@example.org.